12 February 2018
NovaMedica, a Russian pharmaceutical company and the investment project of RUSNANO, has announced the collaboration in the area of knowledge and technology transfer between NovaMedica Innotech, an R&D center, and Evonik, a German company and a leader in the global market of excipients for pharmaceutical industry.
02 February 2018
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab.
02 February 2018
AstraZeneca and Syndax have teamed up to test immune checkpoint inhibitor Imfinzi in combination with CSF1R inhibitor SNDX-6352. Syndax is set to put the cocktail through a phase 1b solid tumor trial to equip both companies to sponsor midphase trials to demonstrate its safety and efficacy.
17 August 2018
Researchers from Cleveland Clinic (Cleveland, Ohio, USA) have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.
16 August 2018
M&A-driven dealmaking in 2018 across the biopharmaceutical industry is on track to becoming the second highest of the decade. “There’s been a significant increase in private financing, principally driven by Series A financing, which tells us that new company formation has accelerated in the last four to five years,” says Neel Patel, managing director, commercial strategy and planning, at Syneos Health Consulting, and co-author of theNeel Patel 2018 Dealmakers’ Intention Study.
15 August 2018
As a small biotech company proceeds from startup phase through rapid growth of its operations, it will face many critical decisions along the way. Indeed, many of the decisions will be pivotal to determining whether the company will successfully move from a small incubator of ideas to the ability to shepherd a R&D asset through its pipeline to achieving commercial success. This article will provide readers with selected examples of such decisions, plus questions or factors to be considered when making decisions that will have significant impact on the future of their growing firm.
14 August 2018
Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).